New Metabolic Disease Articles from our Partners at Consultant 360

Bariatric Surgery Is Linked to Hypertension Improvement, Remission

https://www.consultant360.com/exclusive/cardiology/cardiometabolic-risk/bariatric-surgery-linked-hypertension-improvement

In a recent randomized clinical trial, the effects of bariatric surgery on hypertension severity and management were compared with standard medical therapy.

BMI Is a Stronger Predictor of Diabetes Risk Than Genetics

https://www.consultant360.com/exclusive/endocrinology/diabetes/bmi-stronger-predictor-diabetes-risk-genetics 

Focusing on body mass index over genetics could be vital for identifying individuals with the greatest risk of developing diabetes, according to researchers at ESC Congress 2020.

Lipoic Acid Supplementation: Could It Improve BMI?

https://www.consultant360.com/endocrinology/lipoic-acid-supplementation-could-it-improve-bmi

While it has been suggested that lipoic acid supplementation could be beneficial in the treatment of diabetes, overweight, and other conditions, there is currently a lack of evidence available on its effects in patients with overweight who are otherwise healthy.

Ricardo Cohen, MD, on Bariatric Surgery for the Treatment of CKD in Patients with Obesity and Type 2 Diabetes

https://www.consultant360.com/podcast/consultant360/chronic-kidney-disease/ricardo-cohen-md-bariatric-surgery-treatment-ckd

In this podcast, Dr Cohen discusses his research on the safety and effectiveness of Roux-en-Y gastric bypass surgery for the early treatment of chronic kidney disease among patients with obesity and type 2 diabetes, and how stigmatization of these diseases impacts the frequency with which certain treatment options are made available.

ACC Updates Guidance on Reducing CV Risk Among Patients With Type 2 Diabetes

https://www.consultant360.com/exclusive/cardiology/acc-updates-guidance-reducing-cv-risk-among-patients-type-2-diabetes 

The ACC’s expert consensus decision pathway includes guidance on initiating and monitoring the use of SGLT2 inhibitors and GLP-1RAs among patients with type 2 diabetes for lowering CV risk.